

Clinical trials of immune checkpoint inhibition for lung cancer (metastatic) in second line

TrialResults-center www.trialresultscenter.org

1 PD-L1 inhibitors

Trial	Treatments	Patients	Trials design and methods
atezolizumab vs docetaxel			
OAK , 2016 [NCT02008227] n=425/425 follow-up: minimum 19 months	atezolizumab versus docetaxel	Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy	Parallel groups open label
POPLAR Phase 2 atezolizumab , 2016 [NCT01903993] n=144/143 follow-up:	Atezolizumab versus docetaxel 75 mg/m(2) once every 3 weeks	patients with locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Th	Parallel groups open label 13 countries in Europe and North America
avelumab vs docetaxel			
JAVELIN Lung 200 ongoing [NCT02395172] n=NA follow-up:	avelumab versus docetaxel	subjects with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet	
durvalumab vs Standard of Care			
ARCTIC ongoing [NCT02352948] n=NA follow-up:	-	patients with PD-L1 positive Locally Advanced or Metastatic Non Small Cell Lung Cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC	

References

OAK, 2016:

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017;389:255-265 [27979383]

POPLAR Phase 2 atezolizumab, 2016:

Vansteenkiste J Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) ESMO 2015

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised

controlled trial. Lancet 2016 Mar 9;: [26970723]

Fehrenbacher L, Spira A, Ballinger M, Kowanzetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016 Apr 30;387:1837-46 [26970723]

JAVELIN Lung 200, :

ARCTIC, 0:

2 PD1 inhibitors

Trial	Treatments	Patients	Trials design and methods
AZD9291 durvalumab vs AZD9291 Monotherapy			
CAURAL <i>ongoing</i> [NCT02454933] n=NA follow-up:	MEDI4736 & AZD9291 Combination versus AZD9291 Monotherapy (Once daily tablet 80 mg)	patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy	open label UK
nivolumab vs docetaxel			
CheckMate 057 , 2015 [NCT01673867] n=292/290 follow-up:	Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression versus Docetaxel 75 mg/m concentrate for solution for intravenous infusion every 3 weeks until documented disease progression	patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who had progressed on platinum-doublet chemotherapy	Parallel groups open
CheckMate 017 , 2015 <i>unpublished</i> [NCT01642004] n=135/137 follow-up:	Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression versus Docetaxel 75 mg/m ² solution intravenously every 3 weeks until documented disease progression	patients with advanced SQ NSCLC who fail platinum-based doublet chemotherapy	open
pembrolizumab 10mg vs docetaxel			
Keynote 010 10mg , 2015 [NCT01905657] n=NA follow-up:	pembrolizumab 10 mg/kg versus docetaxel 75 mg/m every 3 weeks	patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells	open-label
pembrolizumab 2mg vs docetaxel			
Keynote 010 2mg , 2015 [NCT01905657] n=345/343 follow-up:	pembrolizumab 2 mg/kg versus docetaxel 75 mg/m every 3 weeks	patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells	Parallel groups open-label
nivolumab for 1 year vs nivolumab			

continued...

Trial	Treatments	Patients	Trials design and methods
CheckMate 153 <i>ongoing</i> [NCT02066636] n=NA follow-up:	Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression versus Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year	patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen	

References

CAURAL, 0:

CheckMate 057, 2015:

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhuf M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin L, Blumenschein GR Jr, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 2015 Oct 22;373:1627-39 [26412456] [10.1056/NEJMoa1507643](https://doi.org/10.1056/NEJMoa1507643)

CheckMate 017, 2015:

Brahmer J, Reckamp KL, Baas P, Crin L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arn Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbis Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med* 2015 May 31;: [26028407] [10.1056/NEJMoa1504627](https://doi.org/10.1056/NEJMoa1504627)

Keynote 010 10mg, 2015:

Herbst RS, Baas P, Kim DW, Felip E, Prez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2015 Dec 18;: [26712084] [10.1016/S0140-6736\(15\)01281-7](https://doi.org/10.1016/S0140-6736(15)01281-7)

Keynote 010 2mg, 2015:

Herbst RS, Baas P, Kim DW, Felip E, Prez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2015 Dec 18;: [26712084] [10.1016/S0140-6736\(15\)01281-7](https://doi.org/10.1016/S0140-6736(15)01281-7)

CheckMate 153, :

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.